Clinical characteristics and pharmacokinetics of PAXLOVID in COVID-19 patients with hematological tumor.
作者信息
Liu Wei, Yang Ping, Yang Ping, Yang Li, Jing Hongmei, Zhao Libo, Zhao Rongsheng
机构信息
Department of Pharmacy, Peking University Third Hospital, Beijing, China.
Therapeutic Drug Monitoring and Clinical Toxicology Center of Peking University, Beijing, China.
出版信息
Med Rev (2021). 2024 Mar 4;4(2):169-171. doi: 10.1515/mr-2023-0068. eCollection 2024 Apr.
Abstract
摘要
相似文献
1
Clinical characteristics and pharmacokinetics of PAXLOVID in COVID-19 patients with hematological tumor.PAXLOVID在血液系统肿瘤COVID-19患者中的临床特征和药代动力学
Med Rev (2021). 2024 Mar 4;4(2):169-171. doi: 10.1515/mr-2023-0068. eCollection 2024 Apr.
2
Clinical efficacy analysis of paxlovid in children with hematological diseases infected with the omicron SARS-CoV-2 new variant.帕罗韦德治疗感染奥密克戎SARS-CoV-2新变种的血液病患儿的临床疗效分析
Front Pediatr. 2023 Apr 25;11:1160929. doi: 10.3389/fped.2023.1160929. eCollection 2023.
3
COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022.2022年1月至6月期间，服用帕罗韦德和莫努匹韦后出现的新冠病毒反弹情况。
medRxiv. 2022 Jun 22:2022.06.21.22276724. doi: 10.1101/2022.06.21.22276724.
4
Paxlovid use is associated with lower risk of cardiovascular diseases in COVID-19 patients with autoimmune rheumatic diseases: a retrospective cohort study.帕克洛维德的使用与 COVID-19 合并自身免疫性风湿病患者的心血管疾病风险降低相关：一项回顾性队列研究。
BMC Med. 2024 Mar 13;22(1):117. doi: 10.1186/s12916-024-03331-0.
5
Postmarketing Reporting of Paxlovid-Related Dysgeusia: A Real-World Pharmacovigilance Study.帕克洛维德相关味觉障碍的上市后报告：一项真实世界的药物警戒研究。
Otolaryngol Head Neck Surg. 2023 Jul;169(1):55-61. doi: 10.1002/ohn.278. Epub 2023 Feb 5.
6
Clinical outcomes of nirmatrelvir-ritonavir use in pregnant women during the Omicron wave of the coronavirus disease 2019 pandemic.2019 年冠状病毒病奥密克戎疫情期间，尼马曲韦/利托那韦在孕妇中的临床结局。
J Infect Public Health. 2023 Dec;16(12):1942-1946. doi: 10.1016/j.jiph.2023.10.007. Epub 2023 Oct 5.
7
Paxlovid Associated with Decreased Hospitalization Rate Among Adults with COVID-19 - United States, April-September 2022.帕克洛维德降低 COVID-19 成年患者住院率-美国，2022 年 4 月-9 月。
MMWR Morb Mortal Wkly Rep. 2022 Dec 2;71(48):1531-1537. doi: 10.15585/mmwr.mm7148e2.
8
COVID-19 rebound after Paxlovid treatment during Omicron BA.5 vs BA.2.12.1 subvariant predominance period.在奥密克戎BA.5与BA.2.12.1亚型毒株占主导期间，帕罗韦德治疗后新冠病毒疾病（COVID-19）的反弹情况
medRxiv. 2022 Aug 6:2022.08.04.22278450. doi: 10.1101/2022.08.04.22278450.
9
Reduced Viral Shedding Time in High-Risk COVID-19 Patients Infected by Omicron and Treated with Paxlovid: A Real-World Study from China.奥密克戎感染的高危COVID-19患者使用帕罗韦德治疗后病毒脱落时间缩短：一项来自中国的真实世界研究
Infect Drug Resist. 2024 Mar 29;17:1267-1279. doi: 10.2147/IDR.S443574. eCollection 2024.
10
Paxlovid for Treating COVID-19 Patients: A Case-Control Study From Two Hospitals in the Eastern Province of Saudi Arabia.帕罗韦德治疗新冠肺炎患者：沙特阿拉伯东部省份两家医院的病例对照研究
Cureus. 2023 May 19;15(5):e39234. doi: 10.7759/cureus.39234. eCollection 2023 May.
本文引用的文献
1
Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients.免疫功能低下患者持续性或复发性严重急性呼吸综合征冠状病毒 2 感染的 2 种抗病毒药物和单克隆抗体三联疗法。
Clin Infect Dis. 2023 Jul 26;77(2):280-286. doi: 10.1093/cid/ciad181.
2
Simultaneous determination of nirmatrelvir and ritonavir in human plasma using LC-MS/MS and its pharmacokinetic application in healthy Chinese volunteers.采用 LC-MS/MS 法同时测定人血浆中奈玛特韦和利托那韦的浓度及其在健康中国志愿者中的药代动力学应用。
Biomed Chromatogr. 2022 Nov;36(11):e5456. doi: 10.1002/bmc.5456. Epub 2022 Aug 5.
3
Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection.用于免疫功能低下且因感染新型冠状病毒而住院的患者的帕罗韦德。
Lancet Infect Dis. 2022 Sep;22(9):1279. doi: 10.1016/S1473-3099(22)00430-3. Epub 2022 Jul 14.
4
Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir.创新的随机I期研究及给药方案选择，以加速并为奈玛特韦的关键COVID-19试验提供信息。
Clin Pharmacol Ther. 2022 Jul;112(1):101-111. doi: 10.1002/cpt.2603. Epub 2022 May 4.
5
SARS-CoV-2 productively infects human gut enterocytes.SARS-CoV-2 能有效地感染人类肠道肠细胞。
Science. 2020 Jul 3;369(6499):50-54. doi: 10.1126/science.abc1669. Epub 2020 May 1.
Zotero 插件